Glycosaminoglycan, Urine

Kidney

Report in 384Hrs

At Home

No Fasting Required

Details

Detects mucopolysaccharides.

₹4,810₹6,871

30% OFF

Glycosaminoglycan Urine Test - Comprehensive Medical Guide

Why is it done?
- Measures urinary excretion of glycosaminoglycans (GAGs), which are complex carbohydrates found in connective tissue, and their abnormal accumulation indicates metabolic disorders
- Screen for lysosomal storage diseases, particularly mucopolysaccharidoses (MPS) such as Hurler syndrome, Hunter syndrome, Sanfilippo syndrome, Morquio syndrome, and Maroteaux-Lamy syndrome
- Diagnose suspected inherited metabolic disorders presenting with progressive skeletal deformities, developmental delay, facial abnormalities, or organomegaly
- Monitor disease progression and response to enzyme replacement therapy (ERT) or gene therapy in patients with confirmed mucopolysaccharidoses
- Performed as first-line screening test when lysosomal storage disease is suspected, typically during childhood when symptoms first appear
- Evaluate family members or siblings of diagnosed patients for early detection and intervention
Normal Range
- Reference Values: Normal urine GAG excretion typically ranges from 0-9 mg/day in adults and 0-15 mg/day in children, though values may vary by laboratory
- Units of Measurement: Milligrams per 24-hour urine collection (mg/24h) or micrograms per hour (μg/h)
- Borderline/Elevated Values: Values 10-15 mg/day may warrant further investigation Values >15 mg/day are consistently abnormal and strongly suggestive of lysosomal storage disease
- Interpretation Categories: Negative/Normal: GAGs within normal range suggests absence of mucopolysaccharidosis Positive/Elevated: Elevated GAG levels indicate storage disease or metabolic disorder
- Important Note: Reference ranges may differ between laboratories; always consult specific laboratory reference values
Interpretation
- Markedly Elevated Results (>50 mg/day): Strongly suggestive of severe mucopolysaccharidosis Often associated with MPS I (Hurler syndrome) or MPS II (Hunter syndrome) Indicates substantial lysosomal dysfunction and accumulation of glycosaminoglycans
- Moderately Elevated Results (15-50 mg/day): Consistent with mucopolysaccharidosis or other glycogen storage disease Warrants further testing including enzyme assays and genetic analysis May indicate attenuated form of MPS or other lysosomal disorders
- Specific GAG Patterns: Elevated dermatan sulfate and heparan sulfate: Suggests MPS I or MPS II Elevated keratan sulfate: Suggests MPS IV (Morquio syndrome) Elevated heparan sulfate: Suggests MPS III (Sanfilippo syndrome) Elevated chondroitin sulfate: Suggests MPS VI (Maroteaux-Lamy syndrome)
- Normal Results: Makes mucopolysaccharidosis unlikely, though does not completely exclude it May indicate normal metabolism or ruled-out lysosomal storage disease Some attenuated forms of MPS may present with borderline or occasionally normal results
- Factors Affecting Results: Urine dilution may falsely lower results Incomplete 24-hour collection may provide inaccurate data Age of patient (children may have slightly higher normal ranges) Hydration status at time of collection Disease stage and disease severity in confirmed cases
- Clinical Significance: Elevated GAG is a hallmark finding in lysosomal storage diseases Test serves as preliminary screening before definitive enzyme assays Degree of elevation often correlates with disease severity Serial monitoring can track disease progression and therapeutic response
Associated Organs
- Primary Systems Involved: Skeletal system: Dysostosis multiplex, joint stiffness, vertebral abnormalities, short stature Urinary system: Kidney involvement, urinary tract complications Connective tissue: Affected by glycosaminoglycan accumulation Lysosomal system: Primary site of metabolic dysfunction
- Conditions Associated with Abnormal Results: Mucopolysaccharidosis Type I (Hurler syndrome): Severe systemic disease Mucopolysaccharidosis Type II (Hunter syndrome): X-linked disorder Mucopolysaccharidosis Type III (Sanfilippo syndrome): Neurological complications Mucopolysaccharidosis Type IV (Morquio syndrome): Skeletal manifestations Mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome): Progressive disorder Other rare lysosomal storage diseases
- Multi-System Complications: Cardiac manifestations: Valvular disease, heart failure Pulmonary complications: Airway obstruction, respiratory insufficiency Hepatosplenomegaly: Organ enlargement due to GAG storage Central nervous system: Developmental delay, progressive neurological decline Vision and hearing: Corneal clouding, hearing loss from storage Dental problems: Abnormal tooth development and eruption
- Associated Health Risks: Progressive disability and loss of function Shortened life expectancy in severe forms (particularly MPS I) Recurrent infections due to immune dysfunction Neurological degeneration in certain subtypes Airway compromise requiring intervention Orthopedic complications and mobility restrictions
- Organ Monitoring Recommendations: Cardiac: Echocardiography and cardiac evaluation Skeletal: Radiological imaging and orthopedic assessment Pulmonary: Lung function testing and airway assessment Neurological: Developmental testing and neuroimaging when indicated Ophthalmological: Eye examinations for corneal involvement Auditory: Hearing assessments and audiometry
Follow-up Tests
- Confirmatory Enzyme Assays (Essential when GAG is elevated): Enzyme testing on leukocytes or fibroblasts Identify which specific enzyme is deficient Performed on blood sample or skin biopsy Definitive diagnostic test for specific MPS type
- Genetic Testing: Molecular genetic analysis to identify specific mutations Confirm diagnosis at molecular level Genetic counseling for family members Determines inheritance pattern and recurrence risks
- Imaging Studies: Skeletal radiography: Assess dysostosis multiplex and bone abnormalities Echocardiography: Evaluate cardiac valve involvement and function MRI of brain: Assess for neurological involvement and white matter changes Chest imaging: Pulmonary involvement and airway assessment
- Specialized Functional Tests: Pulmonary function testing (PFT): Assess respiratory capacity Hearing assessment and audiometry: Detect hearing loss Ophthalmological examination: Screen for corneal clouding and vision problems Developmental/neuropsychological testing: Evaluate neurological status
- Monitoring Protocols for Confirmed Cases: Repeat GAG urine testing: Every 6-12 months to monitor disease progression Serial echocardiograms: Annually or as clinically indicated Periodic neuroimaging: Every 1-2 years for neurological disease Audiological follow-up: Annual hearing assessments Orthopedic evaluations: As needed for mobility and joint concerns Ophthalmological exams: Annual or semi-annual depending on involvement
- Therapy Response Monitoring: GAG urine levels: Assess response to enzyme replacement therapy (ERT) Clinical assessment scores: Measure functional improvement Radiological progression: Monitor skeletal changes Organ-specific markers: Track cardiac, pulmonary, neurological status
- Family Screening Tests: GAG urine testing: Screen siblings and relatives Carrier testing: Identify heterozygous carriers in autosomal recessive forms Prenatal testing: For at-risk pregnancies using amniocentesis or CVS
Fasting Required?
- Fasting Requirement: NO - Fasting is not required for this test
- Sample Collection Method: 24-hour urine collection (most common and preferred method) Random urine specimen (acceptable alternative) First morning urine specimen (in some protocols)
- Special Collection Instructions for 24-Hour Urine: Discard first morning void and begin collection with second void Collect all subsequent urine for exactly 24 hours Collect final specimen at same time on following day Use clean container provided by laboratory No special preservatives typically needed (confirm with lab) Keep container refrigerated or on ice during collection period Ensure proper labeling with patient name, date, and time of collection
- Medications to Avoid: No specific medication restrictions for this test Inform provider of all current medications for context Enzyme replacement therapy (ERT) should NOT be discontinued Continue all regular medications as prescribed Provide medication list to healthcare provider for reference
- Patient Preparation Requirements: Maintain normal hydration status throughout collection Avoid excessive fluid restriction or overconsumption No special dietary restrictions Maintain normal physical activity Collect urine at room temperature; avoid contamination If urinary catheter present, label specimen accordingly
- Important Notes: 24-hour collections ensure accurate quantitation Incomplete collections may result in false-low values Dilute urine may require repeat collection Contact laboratory with collection questions before starting Provide complete and accurate urine volume information Test can be performed in outpatient setting

How our test process works!